THE LATEST NEWS IN CANCER CLINICAL RESEARCH

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer

MEDSIR’s PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer

MEDSIR, Debiopharm, initiate clinical collaboration to explore potential synergy of Debio 0123 & Sacituzumab Govitecan in advanced breast cancer

MEDSIR Presents Two Translational Studies Focused on Biomarkers at AACR2024 Annual Meeting

The Lancet publishes positive results from the PHERGain study in patients with localized HER2-positive breast cancer

Press Release: DEBBRAH Cohort 5 and ATRACTIB trial at San Antonio Breast Cancer Symposium

Press Release: PARSIFAL-LONG at San Antonio Breast Cancer Symposium

Press Release: MiRaDor at San Antonio Breast Cancer Symposium

MEDSIR presents the results of three new studies at ESMO 2023: LUPER, focusing on lung cancer

Phergain Collaborators’ Ecosystem in Spain.

MEDSIR at ASCO 2023

PALMIRA Study at ASCO 2023

PHERGain study at ASCO 2023

Gema Llorente, new corporate CFO of MEDSIR

Rosario Rodríguez, New Chief Trial Officer at MEDSIR

New collaboration between MEDSIR and Dana Farber

Strategic partnership with REVEAL GENOMICS for cancer research

Jyoti Mundra, PhD, appointed as new Chief Business Officer at MEDSIR

MEDSIR and Oncoclínicas sign strategic alliance

MEDSIR signs a strategic alliance with Oncoclínicas to strengthen its international expansion